AGMB: AgomAb Therapeutics NV insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
8 open-market buys totaling $311K and 0 sales totaling - in the last 180 days.
Insider buys
| Score | Ticker | Company | Insider | Role | Trade date | Value | Holding + | Cluster |
|---|---|---|---|---|---|---|---|---|
| 54 | AGMB | AgomAb Therapeutics NV | Epstein David R | Director | 2026-10-08 | $44K | 50% | 3 insiders |
| 62 | AGMB | AgomAb Therapeutics NV | Knotnerus Tim Jasper | CEO | 2026-10-06 | $44K | 30% | 3 insiders |
| 60 | AGMB | AgomAb Therapeutics NV | Kemula Pierre Thadee Victor | CFO | 2026-10-06 | $26K | new | 3 insiders |
| 67 | AGMB | AgomAb Therapeutics NV | Kemula Pierre Thadee Victor | CFO | 2026-10-06 | $43K | 167% | 3 insiders |
| 44 | AGMB | AgomAb Therapeutics NV | Kemula Pierre Thadee Victor | CFO | 2026-10-06 | $17K | 25% | 3 insiders |
| 57 | AGMB | AgomAb Therapeutics NV | Epstein David R | Director | 2026-10-06 | $44K | 100% | 3 insiders |
| 69 | AGMB | AgomAb Therapeutics NV | Knotnerus Tim Jasper | CEO | 2026-10-05 | $51K | 55% | 3 insiders |
| 52 | AGMB | AgomAb Therapeutics NV | Epstein David R | Director | 2026-10-05 | $43K | new | 3 insiders |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.